Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease
06 juin 2024 08h30 HE
|
Vaccinex, Inc.
Patient visits complete in Alzheimer's Disease clinical trial. Company plans to lock database in June and to present topline data in July.
Global Real World Evidence Solutions Market to 2028: Increased Emphasis on Comprehensive RWE Services Drives Growth
03 avr. 2023 04h33 HE
|
Research and Markets
Dublin, April 03, 2023 (GLOBE NEWSWIRE) -- The "Global Real World Evidence Solutions Market Size, Share & Industry Trends Analysis Report By Component, By Therapeutic Area, By End-user, By...
Physeon Positive Clinical Trial Results for its Veinplicity® Device to be Published in The Journal of Vascular Access
01 avr. 2019 09h00 HE
|
Physeon
SCHAFFHAUSEN, Switzerland, April 01, 2019 (GLOBE NEWSWIRE) -- Physeon GmbH, (“Physeon” or the “Company”), a leading developer of medical technology products for venous access, today announced that...
Physeon’s Veinplicity Device Featured on ABC Affiliate KSTP Channel 5
14 févr. 2019 13h42 HE
|
Physeon
SCHAFFHAUSEN, Switzerland, Feb. 14, 2019 (GLOBE NEWSWIRE) -- Physeon GmbH, (“Physeon” or the “Company”), a leading developer of medical technology products for venous access, today announced that...
Mayo Clinic to Conduct US “VIVA” Trial for Veinplicity
04 févr. 2019 08h00 HE
|
Physeon
SCHAFFHAUSEN, Switzerland, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Physeon GmbH (“Physeon” or the “Company”), a leading developer of medical technology products for venous access, today announced that...
Physeon Positive Clinical Trial Results for its Veinplicity® Device Published in The Journal of Vascular Access
21 janv. 2019 08h00 HE
|
Physeon
SCHAFFHAUSEN, Switzerland, Jan. 21, 2019 (GLOBE NEWSWIRE) -- Physeon GmbH, (“Physeon” or the “Company”), a leading developer of medical technology products for venous access, today announced that...
Physeon Bolsters Management Team with New Appointments
17 déc. 2018 08h00 HE
|
Physeon
SCHAFFHAUSEN, Switzerland, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Physeon GmbH (“Physeon” or the “Company”), a leading developer of medical technology products for venous access, today announced the...
Physeon Announces Enrollment of First Patient in US “VIVA” Trial for Veinplicity
12 nov. 2018 09h00 HE
|
Physeon
Important Milestone for Veinplicity Study SCHAFFHAUSEN, Switzerland, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Physeon GmbH (“Physeon” or the “Company”), a leading developer of medical technology...
Physeon Receives Institutional Review Board Approval to Commence US "VIVA" Trial for Veinplicity
29 oct. 2018 08h00 HE
|
Physeon
Recent Clinical Study Indicated Device had a Dilatory Effect 38% Greater than other Common Approaches for Veins Targeted for IV Access. Other studies indicate a First IV Stick Success Much Greater...